目的 探討通竅鼻炎膠囊聯(lián)合氯雷他定治療變應(yīng)性鼻炎的臨床療效。方法 選擇2019年2月-2021年2月在鄭州市第九人民醫(yī)院治療的98例變應(yīng)性鼻炎患者作為研究對(duì)象,按照治療方式不同分為對(duì)照組和治療組,每組各49例。對(duì)照組患者口服氯雷他定片, 1片/次, 1次/d。治療組在對(duì)照組治療的基礎(chǔ)上口服通竅鼻炎膠囊, 2.0 g/次, 3次/d。兩組患者的治療周期均為4周。觀察兩組患者的臨床療效,比較兩組治療前后的臨床癥狀評(píng)分和血清指標(biāo)。結(jié)果 治療后,治療組患者的總有效率(95.92%)高于對(duì)照組(83.67%),組間比較有差異(P<0.05)。治療后,兩組患者的鼻塞評(píng)分、鼻癢評(píng)分、噴嚏評(píng)分、流涕評(píng)分均顯著降低,同組比較有顯著差異(P<0.05);并且治療組臨床癥狀評(píng)分較對(duì)照組降低明顯,組間比較有顯著差異(P<0.05)。治療后,兩組患者的γ干擾素(IFN-γ)水平明顯上升,白細(xì)胞介素-17(IL-17)、嗜酸性細(xì)胞陽(yáng)離子蛋白(ECP)、免疫球蛋白E(IgE)水平明顯降低,同組治療前后比較有顯著差異(P<0.05);并且治療組患者的IFN-γ水平較對(duì)照組上升明顯、IL-17、ECP、IgE水平較對(duì)照組降低明顯,組間比較有顯著差異(P<0.05)。結(jié)論 通竅鼻炎膠囊聯(lián)合氯雷他定片治療變應(yīng)性鼻炎具有較好的療效,可緩解患者臨床癥狀,改善血清指標(biāo)。

Objective To explore the clinical effect of Tongqiao Biyan Capsules combined with Loratadine Tablets in treatment of allergic rhinitis.Methods Patients (98 cases) with allergic rhinitis in Ninth People’s Hospital of Zhengzhou from February 2019 to February 2021 were divided into control and treatment groups according to the treatment method, and each group had 49 cases. Patients in the control group were po administered with Loratadine Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Tongqiao Biyan Capsules on the basis of the control group, 2.0 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the clinical symptom scores and serum indexes in two groups were compared before and after treatment.Results After treatment, the total effective rate of the treatment group (95.92%) was higher than that of the control group (83.67%) (P < 0.05). After treatment, the scores of nasal obstruction, nasal itching, sneezing and runny nose in two groups were significantly lower than those in the same group (P < 0.05), and these scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of IFN-γ in two groups were significantly increased, but the levels of IL-17, ECP, and IgE in two groups were significantly decreased (P < 0.05), and the levels of serum indexes in the treatment group were significantly better than those in the control group (P < 0.05).Conclusion Tongqiao Biyan Capsules combined with Loratadine Tablets in treatment of allergic rhinitis has better therapeutic effect, can alleviate patients’ clinical symptoms and improve serum indexes.

R987

國(guó)家自然科學(xué)基金資助項(xiàng)目(81804057)